Amendment No. 1 to Master Services Agreement between VistaGen Therapeutics, Inc. and Allucent

Contract Categories: Business Finance › Modification Agreements
Summary

VistaGen Therapeutics, Inc. and Allucent have agreed to extend the term of their existing Master Services Agreement for clinical research organization (CRO) services. The agreement will now continue until July 31, 2027, or until all active work orders as of that date are completed or terminated, whichever is later. Additionally, the automatic renewal provision in the original agreement has been removed. All other terms of the original agreement remain unchanged.

Read More Arrow
EX-10.162 4 ex_537097.htm EXHIBIT 10.162 ex_537097.htm

Exhibit 10.162

 

AMENDMENT NO. 1

 

TO

 

MASTER SERVICES AGREEMENT

(For All CRO Services)

 

 

This Amendment (“Amendment No. 1”) is made between VistaGen Therapeutics, Inc., a Nevada corporation having an address at 343 Allerton Avenue, South San Francisco, California 94080 (“VistaGen”) and Allucent (formerly known as Cato Research Ltd.) a North Carolina corporation having an address at 2000 Centregreen Way, Suite 300, Cary, North Carolina 27513 (“Allucent”), and is effective as of June 23, 2022.

 

WHEREAS, VistaGen and Allucent entered into a Master Services Agreement dated July 11, 2017 (the “Agreement”); and

 

WHEREAS, the parties wish to amend the Agreement to extend its term.

 

VistaGen and Allucent therefore agree as follows:

 

AMENDMENT

 

 

1.

The term of the Agreement shall be extended and continue until the later of July 31, 2027, or the expiration or termination of any Work Orders that are active as of that date.
 

2.

The automatic renewal provision in Section 5.1 of the Agreement is deleted going forward as of the effective date of this Amendment No. 1.

 

Except as expressly provided in this Amendment No. 1, the Agreement remains unchanged and in full force and effect.

 

 

[Remainder of page intentionally left blank]

 

 
 

 

Each party is signing this agreement with the party’s authorized signature.

 

 

AGREED TO:   AGREED TO:
         
VISTAGEN THERAPEUTICS, INC.   ALLUCENT
         
         
         
By: /s/ Shawn K. Singh    By: /s/ Richard Shimota
         
Name: Shawn K. Singh, J.D.   Name: Richard Shimota
         
Title: Chief Executive Officer     Title: Chief Financial Officer 
         
Date: June 23, 2022   Date:  6/24/2022    

 

Page 2 of 2